RejuvaTech is an innovation-driven chemistry and delivery platform company focused on protected longevity, bioavailability, and regenerative compound systems.

This section provides a structured overview of intellectual property, regulatory positioning, manufacturing readiness, and integration capabilities for strategic partners.

Detailed technical dossiers, validation data, and regulatory documentation are available under confidentiality agreement.

1. Intellectual Property Framework

RejuvaTech maintains multi-layered protection across chemistry, stabilization, synthesis pathways, and delivery architecture.

Our portfolio includes:

• Stabilized NRH precursor compositions (multi-acid crystalline systems)

• Chloride-free synthetic routes for NRH production

• Broad composition and use claims covering NAD⁺-enhancing formulations

• Multimodal absorption architectures (BioPeak®-NAD)

• Triterpenoid nanocarrier and SNEDDS-based delivery systems

• Novel scalable synthesis methods for regenerative triterpenoids

This dual-layer protection (process + composition/use) establishes enforceable structural differentiation across longevity and regenerative product categories.

Filing documentation and claim strategy summaries are available for structured review.

2. Regulatory Positioning

NRH is being advanced as a New Dietary Ingredient (NDI) under DSHEA.

A comprehensive NDI dossier is in preparation, including:

• Manufacturing specifications

• Impurity profiling

• Stability data

• Exposure modeling

• Safety review framework

Stabilized dual-salt NRH samples are currently being produced for expanded validation testing in Q1 2026.

Upon execution of a confidentiality agreement, RejuvaTech will provide access to regulatory documentation and supporting data for formal diligence review.

3. Platform Performance Overview

RejuvaTech’s core technology platforms are designed to address structural limitations of conventional supplement actives.

NRH Platform

• Stabilized multi-acid crystalline architecture

• Reduced hygroscopic degradation

• Improved storage stability under ICH-relevant conditions

• Distinct intracellular NAD⁺ conversion pathway

BioPeak®-NAD

• Multimodal absorption enhancement

• Targeted-release and nanoemulsion systems

• Enzyme modulation and efflux mitigation

BioPeak®-TR

• Nanocarrier + SNEDDS architecture

• Enhanced solubility of lipophilic triterpenoids

• Dermal and systemic delivery optimization

Technical data summaries and comparative modeling are available under NDA.

4. Manufacturing & GMP Integration

RejuvaTech platforms are engineered for scalable integration into existing GMP manufacturing environments.

Integration support includes:

• Formulation blueprints

• Mixing sequence documentation

• Excipient compatibility guidance

• Stability-oriented packaging recommendations

• Scale-up consultation with partner GMP facilities

This structured tech-transfer model reduces development variability and accelerates commercial deployment.

5. Commercial Readiness & Partnership

RejuvaTech’s platforms are positioned for:

• Premium-tier longevity formulations

• Regenerative dermatology applications

• Portfolio-level SKU enhancement

• Margin expansion through dose optimization

• Protected differentiation in commoditizing categories

We welcome confidential engagement with strategic partners and institutional stakeholders.

6. Confidential Information Access

Detailed materials available under NDA include:

• Full patent claim documentation

• Stability datasets

• Manufacturing process outlines

• Analytical validation summaries

• Regulatory submission materials

• Performance modeling data

To initiate structured diligence discussions, please contact:

[Institutional Contact Email]